Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Hold” by Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has been given a consensus recommendation of “Hold” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $5.00.

GOSS has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Gossamer Bio in a report on Tuesday, May 26th. Barclays downgraded Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. The Goldman Sachs Group cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Finally, Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th.

Gossamer Bio Price Performance

Gossamer Bio stock opened at $0.18 on Friday. The stock has a market cap of $41.64 million, a P/E ratio of -0.22 and a beta of 2.00. The firm’s 50 day moving average price is $0.30 and its 200-day moving average price is $1.50. Gossamer Bio has a 1 year low of $0.14 and a 1 year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.96 million for the quarter, compared to the consensus estimate of $4.67 million. As a group, equities analysts expect that Gossamer Bio will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently added to or reduced their stakes in the stock. Merit Financial Group LLC increased its position in shares of Gossamer Bio by 15.2% during the 4th quarter. Merit Financial Group LLC now owns 155,178 shares of the company’s stock valued at $481,000 after purchasing an additional 20,490 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Gossamer Bio during the fourth quarter valued at $148,000. Tudor Investment Corp ET AL increased its position in Gossamer Bio by 7.8% during the third quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock valued at $132,000 after acquiring an additional 3,639 shares during the last quarter. JPMorgan Chase & Co. increased its position in Gossamer Bio by 114.9% during the third quarter. JPMorgan Chase & Co. now owns 194,369 shares of the company’s stock valued at $511,000 after acquiring an additional 103,922 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Gossamer Bio during the fourth quarter valued at $2,024,000. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.